Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CKS1B | P61024 | 1/20 | 0.59 |
| ▸ | SKP1 | P63208 | 1/20 | 0.59 |
| ▸ | SKP2 | Q13309 | 1/20 | 0.59 |
| ▸ | DRD2 | P14416 | 4/20 | 0.57 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.52 |
| ▸ | PKM | P14618 | 1/20 | 0.52 |
| ▸ | ACACB | O00763 | 11/20 | 0.52 |
| ▸ | ACACA | Q13085 | 9/20 | 0.52 |
| ▸ | NAMPT | P43490 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3199650 | 0.87 | CKS1B (0.58) | CKS1BSKP1SKP2DRD2KDM4E | |
| SCHEMBL4116060 | 0.85 | CKS1B (0.64) | CKS1BSKP1SKP2DRD2KDM4E | |
| SCHEMBL24986986 | 0.85 | CKS1B (0.56) | CKS1BSKP1SKP2DRD2KDM4E | |
| SCHEMBL7716756 | 0.83 | DRD2 (0.51) | CKS1BSKP1SKP2DRD2KDM4E | |
| SCHEMBL3436185 | 0.83 | CKS1B (0.54) | CKS1BSKP1SKP2DRD2KDM4E | |
| SCHEMBL12916519 | 0.81 | GPR119 (0.57) | CKS1BSKP1SKP2DRD2KDM4E | |
| SCHEMBL7093978 | 0.81 | CKS1B (0.52) | CKS1BSKP1SKP2DRD2KDM4E | |
| SCHEMBL14207419 | 0.81 | CKS1B (0.52) | CKS1BSKP1SKP2DRD2KDM4E | |
| SCHEMBL10230218 | 0.81 | CKS1B (0.59) | CKS1BSKP1SKP2DRD2KDM4E | |
| SCHEMBL10230212 | 0.81 | CKS1B (0.59) | CKS1BSKP1SKP2DRD2KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8163746-B2 | Azolecarboxamide derivative | ASTELLAS PHARMA INC. (JP) | 2012-04-24 | — | — | US | disclosed |
| US-8163746-B2 | Azolecarboxamide derivative | ASTELLAS PHARMA INC. (JP) | 2012-04-24 | — | — | US | disclosed |
| US-20090286766-A1 | AZOLECARBOXAMIDE DERIVATIVE | ASTELLAS PHARMA INC. (JP) | 2009-11-19 | — | — | US | disclosed |
| US-20090286766-A1 | AZOLECARBOXAMIDE DERIVATIVE | ASTELLAS PHARMA INC. (JP) | 2009-11-19 | — | — | US | disclosed |
| EP-2009005-A1 | AZOLECARBOXAMIDE DERIVATIVE | Astellas Pharma Inc. (JP) | 2008-12-31 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090286766-A1 | AZOLECARBOXAMIDE DERIVATIVE | GPR17, NTRK1, TRPV1 | CKS1B 730/4885SKP1 3148/4885SKP2 241/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.